These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 24604684)

  • 41. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
    Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
    Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Botulinum toxin type A therapy for blepharospasm.
    Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004900. PubMed ID: 15674969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
    Jost WH; Kohl A
    J Neurol; 2001 Apr; 248 Suppl 1():21-4. PubMed ID: 11357234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of facial spasm with botulin A toxin].
    Adenis JP; Smolik I; Maes S
    J Fr Ophtalmol; 1990; 13(5):259-64. PubMed ID: 2258549
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Botulinum toxin in the management of facial paralysis.
    Cabin JA; Massry GG; Azizzadeh B
    Curr Opin Otolaryngol Head Neck Surg; 2015 Aug; 23(4):272-80. PubMed ID: 26101876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Botulinium toxin in ENT].
    Klap P
    Ann Otolaryngol Chir Cervicofac; 2006 Dec; 123(6):306-11. PubMed ID: 17202988
    [No Abstract]   [Full Text] [Related]  

  • 47. Botulinum toxin A and the face.
    Reichel G
    Curr Probl Dermatol; 2002; 30():236-45. PubMed ID: 12471716
    [No Abstract]   [Full Text] [Related]  

  • 48. [Mechanism of therapy effects by botulinum neurotoxin].
    Alajbegović A; Alajbegović S; Resić H
    Med Arh; 2008; 62(1):53-5. PubMed ID: 18543757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of botulinum toxin in ophthalmology.
    Denniston A; Reuser T
    Hosp Med; 2001 Aug; 62(8):477-9. PubMed ID: 11530585
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Five decades of the use of botulinum toxin in ophthalmology.
    Leszczynska A; Nowicka D; Pillunat LE; Szepietowski JC
    Indian J Ophthalmol; 2024 Jun; 72(6):789-795. PubMed ID: 38317306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic uses of botulinum toxin: from facial palsy to autonomic disorders.
    de Maio M
    Expert Opin Biol Ther; 2008 Jun; 8(6):791-8. PubMed ID: 18476790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of botulinum toxin type A following long-term use.
    Naumann M; Albanese A; Heinen F; Molenaers G; Relja M
    Eur J Neurol; 2006 Dec; 13 Suppl 4():35-40. PubMed ID: 17112348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advanced functional oculofacial indications of botulinum toxin.
    Lee C; Kikkawa DO; Pasco NY; Granet DB
    Int Ophthalmol Clin; 2005; 45(3):77-91. PubMed ID: 15970767
    [No Abstract]   [Full Text] [Related]  

  • 54. The use of botulinum toxin in head and face medicine: an interdisciplinary field.
    Laskawi R
    Head Face Med; 2008 Mar; 4():5. PubMed ID: 18331633
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm.
    Wabbels B; Jost WH; Roggenkämper P
    J Neural Transm (Vienna); 2011 Jun; 118(6):925-43. PubMed ID: 21221669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Benign essential blepharospasm.
    McCann JD; Ugurbas SH; Goldberg RA
    Int Ophthalmol Clin; 2002; 42(2):113-21. PubMed ID: 11914708
    [No Abstract]   [Full Text] [Related]  

  • 57. Benign essential blepharospasm.
    Ben Simon GJ; McCann JD
    Int Ophthalmol Clin; 2005; 45(3):49-75. PubMed ID: 15970766
    [No Abstract]   [Full Text] [Related]  

  • 58. Botulinum Toxin in the Treatment of Facial Paralysis.
    Mehdizadeh OB; Diels J; White WM
    Facial Plast Surg Clin North Am; 2016 Feb; 24(1):11-20. PubMed ID: 26611697
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral Pharmacotherapy for Benign Essential Blepharospasm.
    Hirabayashi KE; Vagefi MR
    Int Ophthalmol Clin; 2018; 58(1):33-47. PubMed ID: 29239876
    [No Abstract]   [Full Text] [Related]  

  • 60. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years.
    Streitová H; Bareš M
    Acta Neurol Belg; 2014 Dec; 114(4):285-91. PubMed ID: 24604684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.